Envoy Medical, Inc Warrant financials
$0.0317+4.97%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.0K | $39.0K | $75.0K | $42.0K | $78.0K | $46.0K | $42.0K | $56.0K | $68.0K | $59.0K | $95.0K |
| Gross profit | -$227.0K | -$274.0K | -$136.0K | -$161.0K | -$156.0K | -$180.0K | -$115.0K | -$131.0K | -$177.0K | -$94.0K | -$139.0K |
| Gross margin | −445.1% | −702.6% | −181.3% | −383.3% | −200.0% | −391.3% | −273.8% | −233.9% | −260.3% | −159.3% | −146.3% |
| Operating income | -$5.6M | -$6.0M | -$6.4M | -$5.7M | -$5.1M | -$5.1M | -$4.5M | -$5.0M | -$4.9M | -$4.9M | -$6.7M |
| Net income | -$7.3M | -$5.7M | -$7.7M | -$7.7M | -$6.9M | -$6.2M | -$7.7M | -$7.3M | -$5.3M | -$7.6M | -$6.2M |
| Net margin | −14258.8% | −14617.9% | −10316.0% | −18445.2% | −8900.0% | −13556.5% | −18300.0% | −13107.1% | −7811.8% | −12940.7% | −6572.6% |
| Diluted EPS | $-0.07 | $-0.08 | $-0.27 | $-0.35 | $-0.32 | $-0.29 | $-0.40 | $-0.39 | $-0.29 | $-0.41 | $-0.35 |
| EBITDA | -$5.5M | -$5.9M | -$6.3M | -$5.6M | -$5.0M | -$5.0M | -$4.5M | -$4.9M | -$4.8M | -$4.8M | -$6.7M |
| Operating cash flow | -$5.5M | -$6.1M | -$5.7M | -$4.3M | -$4.5M | -$3.7M | -$5.1M | -$2.6M | -$4.6M | -$5.6M | -$11.1M |
| Free cash flow | -$5.5M | -$6.1M | -$5.9M | -$4.3M | -$4.5M | -$3.7M | -$5.6M | -$3.2M | -$5.4M | -$5.7M | -$11.2M |
| Diluted shares | 104.0M | 68.9M | 28.5M | 21.9M | 21.4M | 21.3M | 19.3M | 18.6M | 18.6M | 18.6M | 17.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.7M | $25.3M | $3.7M | $3.6M | $5.3M | $5.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $23.9M | $29.8M | $8.6M | $8.2M | $9.9M | $10.4M |
| Total liabilities | $20.3M | $19.3M | $20.3M | $15.7M | $39.8M | $34.6M |
| Shareholders' equity | $3.3M | $10.2M | -$12.2M | -$7.7M | -$29.9M | -$24.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology